A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies
- Determine response rate (RR; complete and partial response [CR, PR]) and duration after
therapy with Aroplatin™ in patients with advanced solid malignancies.
- Determine the safety and tolerability of Aroplatin
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
|John Wayne Cancer Institute||Santa Monica, California 90404|